J P Morgan Chase & Co reaffirmed their neutral rating on shares of Smith & Nephew plc (LON:SN) in a report published on Monday, November 6th, MarketBeat reports. The firm currently has a GBX 1,382 ($18.18) price objective on the stock.
A number of other brokerages have also commented on SN. Deutsche Bank AG increased their price objective on Smith & Nephew plc from GBX 1,200 ($15.78) to GBX 1,315 ($17.30) and gave the company a hold rating in a research report on Monday, October 23rd. Jefferies Group LLC reiterated a buy rating and issued a GBX 1,515 ($19.93) price objective on shares of Smith & Nephew plc in a research report on Thursday, October 12th. Citigroup Inc. reiterated a sell rating and issued a GBX 1,160 ($15.26) price objective on shares of Smith & Nephew plc in a research report on Thursday, October 12th. Goldman Sachs Group, Inc. (The) reiterated a neutral rating and issued a GBX 1,380 ($18.15) price objective on shares of Smith & Nephew plc in a research report on Monday, September 11th. Finally, Berenberg Bank reiterated a hold rating and issued a GBX 1,340 ($17.62) price objective on shares of Smith & Nephew plc in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of GBX 1,302.83 ($17.14).
Smith & Nephew plc (SN) opened at GBX 1,344 ($17.68) on Monday. Smith & Nephew plc has a 12-month low of GBX 1,064.91 ($14.01) and a 12-month high of GBX 1,442 ($18.97).
ILLEGAL ACTIVITY WARNING: “Smith & Nephew plc (LON:SN) Receives “Neutral” Rating from J P Morgan Chase & Co” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://ledgergazette.com/2017/11/17/smith-nephew-plc-sn-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.
About Smith & Nephew plc
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.